NCT05433922 (SAA) is a NA clinical trial of Avatrombopag in Severe Aplastic Anemia, sponsored by Institute of Hematology & Blood Diseases Hospital, China.

Who is sponsoring NCT05433922?

NCT05433922 is sponsored by Institute of Hematology & Blood Diseases Hospital, China.

What drugs are being tested in NCT05433922?

Interventions in NCT05433922: Avatrombopag.

What condition does NCT05433922 study?

NCT05433922 studies Severe Aplastic Anemia.

Is NCT05433922 still recruiting?

NCT05433922 is currently status unknown. Last updated 27 June 2022.

Last reviewed 2022-06-27 · How we verify

NCT05433922: SAA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly

Status unknown NA Last updated 27 June 2022

What this trial tests

NA trial testing Avatrombopag in Severe Aplastic Anemia in 80 participants. Status unknown.

Timeline

1 June 2022

Primary endpoint
31 December 2023

31 December 2024

Quick facts

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	1 June 2022
Primary completion	31 December 2023
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

Avatrombopag (AVATROMBOPAG) — full drug profile →

Conditions studied

Severe Aplastic Anemia — all drugs for Severe Aplastic Anemia →

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Who can join

60 and older, any sex, with Severe Aplastic Anemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, single-arm clinical study. The objective was to evaluate the efficacy and safety of CSA in combination with Avatrombopag in elderly patients with very/sever aplastic anemia treated for the first time. The design was: cyclosporine 3 mg/kg orally in two divided doses, with cyclosporine trough concentrations maintained at 200-250 ng/ml for 3 months to achieve maximum efficacy, and Avatrombopag, which was administered in two dose groups, 40 mg orally once daily and 60 mg orally once daily, for a total of 24 weeks. Forty patients are expected to be enrolled in each dose group, and a total of 80 patients are expected to be enrolled if both dose groups are conducted. Evaluation endpoint: OR rate at 24 weeks of treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Avatrombopag

Trials testing the same drug.

NCT07051915 — The Holistic Study · Phase 3 · not yet recruiting
NCT06254287 — Efficacy and Safety of Avatrombopag vs. Avatrombopag Combined With rhTPO in the Treatment of SAA · Phase 2 · unknown
NCT05772546 — Avatrombopag vs. Placebo for CIT in GI Malignancies · Phase 2 · active not recruiting
NCT05996393 — CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly · Phase 4 · completed
NCT06001567 — Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC · Phase 2 · unknown

Other recruiting trials for Severe Aplastic Anemia

Currently open trials in the same condition.

NCT06622694 — CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia · Phase 1 · recruiting
NCT06517641 — Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia · Phase 2 · recruiting
NCT06695741 — Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia · Phase 2 · recruiting
NCT06412497 — MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Se · Phase 2 · recruiting
NCT06378060 — Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia · Phase 2 · recruiting

Other Institute of Hematology & Blood Diseases Hospital, China trials

Trials by the same sponsor.

NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05433922 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
Last refreshed: 27 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05433922.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing